Novel compounds, ‘1,3-selenazine derivatives’ as specific inhibitors of eukaryotic elongation factor-2 kinase
- 24 July 2000
- journal article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1475 (3) , 207-215
- https://doi.org/10.1016/s0304-4165(00)00061-1
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- 1a-Docosahexaenoyl Mitomycin C: A Novel Inhibitor of Protein Tyrosine KinaseBiochemical and Biophysical Research Communications, 1998
- Modulators of signal transduction as cancer chemotherapeutic agents — novel mechanisms and toxicitiesToxicology Letters, 1995
- Labeling of v‐Src and BCR‐ABL tyrosine kinases with [14C]herbimycin A and its use in the elucidation of the kinase inactivation mechanismFEBS Letters, 1994
- Rottlerin, a Novel Protein Kinase InhibitorBiochemical and Biophysical Research Communications, 1994
- Elongation factor‐2 kinase: effective inhibition by the novel protein kinase inhibitor rottlerin and relative insensitivity towards staurosporineFEBS Letters, 1994
- Regulation of elongation factor‐2 by multisite phosphorylationEuropean Journal of Biochemistry, 1993
- Selenonthiol esters: isolation and characterizationJournal of the American Chemical Society, 1993
- The BCR gene encodes a novel serine/threonine kinase activity within a single exonCell, 1991
- Nerve Growth Factor‐Induced Down‐Regulation of Calmodulin‐Dependent Protein Kinase III in PC12 Cells Involves Cyclic AMP‐Dependent Protein KinaseJournal of Neurochemistry, 1990
- Irreversible inhibition of v-src tyrosine kinase activity by herbimycin a and its abrogation by sulfhydryl compoundsBiochemical and Biophysical Research Communications, 1989